Wellgistics Health (WGRX) announced a strategic collaboration with TheracosBio, the manufacturer of Brenzavvy, to make diabetes medications more affordable and accessible across the U.S. healthcare system. The joint effort leverages Wellgistics Health’s “maker-to-taker” platform – a direct pipeline that connects manufacturers to pharmacies and patients while bypassing costly intermediaries. With over 6,500 independent and chain pharmacies in its national network, Wellgistics Health will expand access to Brenzavvy through both traditional retail and direct-to-patient delivery models.Brenzavvy will be integrated into the Wellgistics Tech & Hub and Distribution platform beginning in Q4 2025, enabling immediate patient onboarding through affiliated pharmacies and direct-to-patient channels. Q4 2025 rollout positions WGRX for near-term revenue impact.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGRX: